Toll Free: 1-888-928-9744

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 88 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2016', provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)
- The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects
- The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Primary Progressive Multiple Sclerosis (PPMS) Overview 6 Therapeutics Development 7 Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview 7 Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies 8 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies 11 Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development 12 AB Science SA 12 F. Hoffmann-La Roche Ltd. 13 Genzyme Corporation 14 Kyorin Pharmaceutical Co., Ltd. 15 MedDay 16 Santhera Pharmaceuticals Holding AG 17 Teva Pharmaceutical Industries Limited 18 Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ApE - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 biotin - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GZ-402668 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ibudilast - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 idebenone - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 laquinimod sodium - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 masitinib - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ocrelizumab - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Stem Cell Therapy for CNS Disorders - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Primary Progressive Multiple Sclerosis (PPMS) - Recent Pipeline Updates 50 Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects 79 Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products 80 Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones 81 Featured News & Press Releases 81 Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 81 Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 81 Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS 83 Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS 84 Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 85 Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 85 Appendix 87 Methodology 87 Coverage 87 Secondary Research 87 Primary Research 87 Expert Panel Validation 87 Contact Us 87 Disclaimer 88
List of Tables
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H1 2016 12 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 13 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H1 2016 14 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 15 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay, H1 2016 16 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 17 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Primary Progressive Multiple Sclerosis (PPMS) Therapeutics - Recent Pipeline Updates, H1 2016 50 Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H1 2016 79 Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H1 2016 80


List of Figures
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Top 10 Targets, H1 2016 20 Number of Products by Stage and Top 10 Targets, H1 2016 20 Number of Products by Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify